Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Provided By GlobeNewswire
Last update: Jan 28, 2025
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2
Planned workforce reduction of approximately 40% of employees
Read more at globenewswire.com
